ERR2208947
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.400
- G2M_CHECKPOINT+0.400
- MYC_TARGETS_V2+0.400
- MYC_TARGETS_V1+0.300
- DNA_REPAIR+0.200
- OXIDATIVE_PHOSPHORYLATION+0.200
- PROTEIN_SECRETION+0.200
- GLYCOLYSIS+0.100
- MITOTIC_SPINDLE+0.100
- SPERMATOGENESIS+0.100
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.500
- COMPLEMENT-0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- IL6_JAK_STAT3_SIGNALING-0.500
- INFLAMMATORY_RESPONSE-0.500
- TNFA_SIGNALING_VIA_NFKB-0.500
- ANGIOGENESIS-0.400
- COAGULATION-0.400
- IL2_STAT5_SIGNALING-0.400
- KRAS_SIGNALING_UP-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG81 | — | — | 0.932 |
| 2 | MNG82 | — | — | 0.928 |
| 3 | BS_2A5R9MEJ | high-grade glioma | — | 0.918 |
| 4 | SAMN03290891 | — | — | 0.915 |
| 5 | SAMN03290898 | — | — | 0.913 |
| 6 | BS_K74PZET7 | medulloblastoma | — | 0.912 |
| 7 | TCGA-66-2793-01A-01R-1201-07 | — | cohortMD1 | 0.909 |
| 8 | TCGA-DK-AA6U-01A-11R-A39I-07 | — | — | 0.908 |
| 9 | BS_1HQ76V6D | Embryonal tumors | — | 0.908 |
| 10 | SRR975551 | — | — | 0.907 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.100 | Idelalisib | — uncovered |